Sulfinpyrazone

Clinical data
Trade names	Anturan, Anturane, Apo-sulfinpyrazone
AHFS/Drugs.com	Monograph
MedlinePlus	a682339
Routes of administration	By mouth intravenous
ATC code	M04AB02 (WHO)
Pharmacokinetic data
Protein binding	98–99%
Metabolism	liver
Excretion	kidney
Identifiers
IUPAC name 1,2-diphenyl-4-[2-(phenylsulfinyl)ethyl]pyrazolidine-3,5-dione
CAS Number	57-96-5 Y
PubChem CID	5342
IUPHAR/BPS	5826
DrugBank	DB01138 Y
ChemSpider	5149 Y
UNII	V6OFU47K3W
KEGG	D00449 Y
ChEBI	CHEBI:9342 Y
ChEMBL	ChEMBL832 Y
CompTox Dashboard (EPA)	DTXSID0023618
ECHA InfoCard	100.000.325
Chemical and physical data
Formula	C23H20N2O3S
Molar mass	404.48 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C2N(c1ccccc1)N(C(=O)C2CCS(=O)c3ccccc3)c4ccccc4
InChI InChI=1S/C23H20N2O3S/c26-22-21(16-17-29(28)20-14-8-3-9-15-20)23(27)25(19-12-6-2-7-13-19)24(22)18-10-4-1-5-11-18/h1-15,21H,16-17H2 Y Key:MBGGBVCUIVRRBF-UHFFFAOYSA-N Y
(verify)

Sulfinpyrazone is a uricosuric medication used to treat gout. It also sometimes is used to reduce platelet aggregation by inhibiting degranulation of platelets which reduces the release of ADP and thromboxane.

Like other uricosurics, sulfinpyrazone works by competitively inhibiting uric acid reabsorption in the proximal tubule of the kidney.

Contraindications[edit]

Sulfinpyrazone must not be used in persons with renal impairment or a history of uric acid kidney stones.^[1]

Research[edit]

Trial have found that, Sulfinpyrazone taken in specific daily dose immediately following a patient having suffered from a myocardial infarction seem to drastically reduce the incidence of sudden death by as much as 43% and cardiac mortality by 32% in the 24 months following their heart attack. ^[2]

References[edit]